Chester Mathis | Academic Influence

Chester Mathis's AcademicInfluence.com Rankings

Chester Mathis

Biology

#8966

World Rank

#12113

Historical Rank

Molecular Biology

#1177

World Rank

#1203

Historical Rank

biology Degrees

Download Badge

Biology

Chester Mathis's Degrees

Bachelors Biology University of California, Berkeley
PhD Molecular Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Chester Mathis Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Chester Mathis is an American chemist who is currently the Distinguished Professor of Radiology at University of Pittsburgh and holds the UPMC Endowed Chair of PET Research. He is known for is work with William E. Klunk on a PET radiotracer for imaging amyloid, a protein linked to neurodegenerative diseases including Alzheimer’s. His efforts led to the creation of a novel category of high-efficacy radiopharmaceutical agents, for example Pittsburgh Compound-B , which can be used to assess beta-amyloid in the living human brain using PET scanning, and which is a fluorescent analog of thioflavin T. For his work on Alzheimer's disease he has received the Metlife Foundation Award and the Potamkin Prize .

(See a Problem?)

Chester Mathis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B (2004) (4136)
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory (2005) (1905)
Frequent amyloid deposition without significant cognitive impairment among the elderly. (2008) (978)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans (2006) (968)
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. (2003) (918)
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease (2008) (888)
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. (2008) (876)
[11C]PIB in a nondemented population (2006) (767)
β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease (2007) (719)
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease (2011) (718)
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria (2001) (702)
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009) (701)
Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B (2005) (677)
Pet imaging of serotonin 1A receptor binding in depression (1999) (662)
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. (2009) (632)
Imaging β-amyloid burden in aging and dementia (2007) (610)
Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue (2015) (553)
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. (2005) (546)
The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET (2015) (536)
Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. (2003) (513)
Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging (1998) (504)
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core (2010) (491)
Regional Cerebral Metabolic Alterations in Dementia of the Alzheimer Type: Positron Emission Tomography with [1818] Fluorodeoxyglucose (1983) (487)
Potential antecedent marker of Alzheimer disease (2006) (474)
Relationships between biomarkers in aging and dementia (2009) (440)
Imaging amyloid deposition in Lewy body diseases (2008) (434)
Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance (2008) (418)
Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. (2001) (410)
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. (2007) (409)
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy (2007) (398)
Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain (2005) (384)
Serotonin-1A receptor imaging in recurrent depression: replication and literature review. (2007) (377)
P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees (2006) (367)
Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative (2002) (364)
Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods (2013) (349)
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. (2007) (349)
11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration (2007) (347)
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. (2002) (330)
Amyloid imaging in mild cognitive impairment subtypes (2009) (320)
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia (2006) (315)
Increased Dopamine D2/D3 Receptor Binding After Recovery from Anorexia Nervosa Measured by Positron Emission Tomography and [11C]Raclopride (2005) (312)
The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component (2003) (293)
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB (2010) (272)
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice (2003) (253)
11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment (2008) (240)
Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. (1992) (229)
Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain (2004) (212)
Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve (2009) (212)
Serotonin type-1A receptor imaging in depression. (2000) (203)
Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease (2008) (199)
Serotonin 1A Receptor Binding and Treatment Response in Late-Life Depression (2004) (194)
Diminished Glucose Transport in Alzheimer's Disease: Dynamic PET Studies (1991) (188)
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. (2005) (185)
Altered 5-HT2A Receptor Binding after Recovery from Bulimia-Type Anorexia Nervosa: Relationships to Harm Avoidance and Drive for Thinness (2004) (179)
Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies (2017) (173)
Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. (2005) (171)
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 (2015) (170)
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. (2009) (168)
Serotonin alterations in anorexia and bulimia nervosa: New insights from imaging studies (2005) (164)
Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study (2000) (162)
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease (2005) (162)
PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. (1999) (159)
Amyloid burden and neural function in people at risk for Alzheimer's Disease (2014) (157)
Development of positron emission tomography β-amyloid plaque imaging agents. (2012) (152)
Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults (2013) (150)
Arterial stiffness and β-amyloid progression in nondemented elderly adults. (2014) (146)
Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34 (2001) (146)
Imaging of CNS myelin by positron-emission tomography. (2006) (145)
Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa (2007) (140)
SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0 (2016) (135)
Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. (2014) (134)
PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET (2009) (131)
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials (2015) (130)
Positron emission tomography imaging of amphetamine‐induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride (2009) (129)
Imaging Alzheimer Pathology in Late-Life Depression With PET and Pittsburgh Compound-B (2008) (129)
Molecular targets. (2006) (129)
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects (2010) (126)
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease (2006) (124)
A radiosynthesis of fluorine-18 fluoromisonidazole. (1989) (124)
PET Measures of Amphetamine-Induced Dopamine Release in Ventral versus Dorsal Striatum (1999) (120)
Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology (2018) (118)
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B (2012) (117)
Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson’s disease (2007) (117)
Gender-specific aging effects on the serotonin 1A receptor (2001) (116)
Regional cerebral glucose transport and utilization in Alzheimer's disease (1989) (115)
Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements (2009) (114)
Impact of amyloid imaging on drug development in Alzheimer's disease. (2007) (112)
Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. (2014) (111)
Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. (2015) (108)
Functional connectivity in autosomal dominant and late-onset Alzheimer disease. (2014) (106)
Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease (2005) (105)
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases (2012) (104)
Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. (2011) (101)
In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. (2011) (101)
Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques (2012) (101)
Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease (2010) (100)
Clinical Studies of Cerebral Blood Flow in Alzheimer's Disease (1997) (100)
[11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. (1994) (99)
Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. (2009) (97)
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (96)
Imaging Amyloid-β Deposits In Vivo (2002) (96)
Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study (2015) (94)
Cortical cholinergic denervation is associated with depressive symptoms in Parkinson’s disease and parkinsonian dementia (2007) (94)
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease (2007) (92)
In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects (2013) (92)
Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. (2003) (91)
11 CPIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration (2007) (90)
The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation (2008) (90)
A comparison of the high‐affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)‐PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation (2007) (87)
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. (2012) (84)
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study (2012) (83)
A Comparative Evaluation of the Dopamine D2/3 Agonist Radiotracer [11C](−)-N-Propyl-norapomorphine and Antagonist [11C]Raclopride to Measure Amphetamine-Induced Dopamine Release in the Human Striatum (2010) (78)
Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B (2008) (76)
Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease (2011) (76)
Amyloid-β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. (2015) (75)
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection (2016) (75)
Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches (2013) (74)
Test–retest variability of serotonin 5‐HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain (1998) (74)
Small-molecule PET Tracers for Imaging Proteinopathies. (2017) (74)
Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia (2013) (74)
Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. (2004) (71)
Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. (2005) (71)
Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. (2015) (71)
Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa (2013) (70)
Markers of cholesterol transport are associated with amyloid deposition in the brain (2014) (70)
Serotonin transporter binding after recovery from eating disorders (2007) (70)
Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern? (2008) (70)
Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns (2017) (69)
The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: Implications for PET imaging (2007) (68)
Tiagabine Increases [11C]flumazenil Binding in Cortical Brain Regions in Healthy Control Subjects (2009) (66)
Measurement of 5‐HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY‐100635 (2007) (66)
The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B (2016) (64)
Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand (1989) (63)
Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET (2015) (62)
Analyses of [18F]altanserin bolus injection PET data. II: Consideration of radiolabeled metabolites in humans (2001) (62)
Development of a PET/SPECT agent for amyloid imaging in Alzheimer’s disease (2007) (61)
[F‐18]AV‐1451 positron emission tomography retention in choroid plexus: More than “off‐target” binding (2016) (59)
Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease (2007) (59)
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans (2012) (59)
PET imaging of brain macrophages using the peripheral benzodiazepine receptor in a macaque model of neuroAIDS. (2004) (58)
Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. (1996) (56)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
Association of Brain Amyloid-&bgr; With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E &egr;4 Genotype (2017) (56)
Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort (2011) (52)
Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa. (2012) (52)
Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects (2015) (52)
Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population (2017) (52)
[125I]-2-(2,5-Dimethoxy-4-Iodophenyl) aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex (1990) (52)
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease (2012) (52)
X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. (2006) (51)
Positron emission tomography radioligands for in vivo imaging of Aβ plaques. (2013) (51)
Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old (2014) (51)
Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment (2006) (50)
Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives (2007) (50)
Amyloid imaging in dementias with atypical presentation (2012) (50)
Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET (2010) (50)
Discussion of targeting proteins in vivo: in vitro guidelines. (2006) (49)
Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration. (2008) (45)
Binding to the serotonin 5-HT2 receptor by the enantiohers of 125I-DOI (1987) (45)
Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease (2002) (45)
Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition (2018) (45)
Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [11C]FLB 457: Reproducibility studies (2011) (44)
Imaging amyloid-beta deposits in vivo. (2002) (44)
Brain pH response to hyperventilation in panic disorder: preliminary evidence for altered acid-base regulation. (2006) (43)
Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals (2011) (42)
[125I]5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hyfroxytryptamine uptake complex. I. In vitro studies (1993) (42)
Evaluation of dopamine D2/3specific binding in the cerebellum for the positron emission tomography radiotracer [11C]FLB 457: Implications for measuring cortical dopamine release (2011) (41)
In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed tomography and [123I]5-iodo-6-nitroquipazine. (1993) (41)
Effect of S-equol and Soy Isoflavones on Heart and Brain (2019) (41)
In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. (2012) (41)
Regional cerebral blood flow after recovery from anorexia or bulimia nervosa. (2007) (40)
Synthesis and in vitro evaluation of 2,3-dimethoxy-5-(fluoroalkyl)-substituted benzamides: high-affinity ligands for CNS dopamine D2 receptors. (1991) (39)
b -amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease (2007) (39)
Targeting proteins in vivo: in vitro guidelines. (2006) (39)
Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease (2014) (39)
Labeled choline and phosphorylcholine: body distribution and brain autoradiography: concise communication. (1983) (38)
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status (2014) (38)
[11C]flumazenil Binding Is Increased in a Dose-Dependent Manner with Tiagabine-Induced Elevations in GABA Levels (2012) (36)
Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging (2018) (35)
Synthesis and beta-amyloid binding properties of rhenium 2-phenylbenzothiazoles. (2009) (35)
Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C]ABP688 (2015) (35)
Large-scale genomics unveil polygenic architecture of human cortical surface area (2015) (34)
Autoradiographic localization of binding sites for 125I-DOI, a new psychotomimetic radioligand, in the rat brain. (1987) (33)
Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems! (2009) (33)
Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities (2013) (33)
EFFECTS OF SOY ISOFLAVONES ON COGNITIVE FUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (2018) (33)
Relationship of a 5-HT transporter functional polymorphism to 5-HT1A receptor binding in healthy women (2005) (32)
xaggerated 5-HT 1 A but Normal 5-HT 2 A Receptor ctivity in Individuals Ill with Anorexia Nervosa (2007) (32)
[125I]5-iodo-6-nitro-2-piperazinylquinoline: a potent and selective ligand for the serotonin uptake complex. (1992) (31)
Targeting Prion Amyloid Deposits In Vivo (2004) (31)
Quantitative in vitro and ex vivo autoradiography of the α2-adrenoceptor antagonist [3H]atopamezole (1992) (31)
Amyloid &bgr; Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia (2018) (30)
Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality (2018) (30)
Gallium-68 lipophilic complexes for labeling platelets. (1985) (29)
Positron emission tomography imaging of D2/3 agonist binding in healthy human subjects with the radiotracer [11C]‐N‐propyl‐norapomorphine: Preliminary evaluation and reproducibility studies (2009) (28)
Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
Imaging of dopamine D2/3 agonist binding in cocaine dependence: A [11C]NPA positron emission tomography study (2011) (27)
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. (2006) (27)
(R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes. (1988) (26)
Quantitative assessment of glucose transport in human skeletal muscle: dynamic positron emission tomography imaging of [O-methyl-11C]3-O-methyl-D-glucose. (2005) (26)
5-HT₁A receptor binding is increased after recovery from bulimia nervosa compared to control women and is associated with behavioral inhibition in both groups. (2011) (26)
Serotonin transporter binding after recovery from eating disorders (2007) (26)
Comparison of the amyloid imaging agents [F-18]3'-F-PIB and [C-11]PIB in Alzheimer's disease and control subjects (2007) (25)
Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study (2002) (25)
Analyses of [18F]altanserin bolus injection PET data. I: Consideration of radiolabeled metabolites in baboons (2001) (25)
Sleep moderates the relationship between amyloid beta and memory recall (2018) (25)
Reduced binding of Pittsburgh Compound-B in areas of white matter hyperintensities (2015) (25)
Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. (2002) (24)
Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter. (1999) (24)
Preventive immunization of aged and juvenile non-human primates to beta-amyloid (2012) (23)
Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP Mice. (2009) (23)
Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome. (2017) (22)
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease (2020) (22)
18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
Tenascin-C Is Associated with Cored Amyloid-&bgr; Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly (2016) (21)
Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects (2021) (21)
Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia (2017) (21)
The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods (2018) (21)
Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture (2013) (21)
Binding Potency of Paroxetine Analogues for the 5‐Hydroxytryptamine Uptake Complex * (1992) (20)
Dopaminergic activity and altered reward modulation in anorexia nervosa—insight from multimodal imaging (2017) (19)
Amyloid accumulation in Down syndrome measured with amyloid load (2020) (19)
Synthesis and 11C-labelling of (E,E)-1-(3′,4′-dihydroxystyryl)-4-(3′-methoxy-4′-hydroxystyryl) benzene for PET imaging of amyloid deposits†† (2002) (19)
A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
CHAPTER 16 – Scatter Correction for Brain Receptor Quantitation in 3D PET (1996) (19)
Evaluation of [3H]paroxetine as an in vivo ligand for serotonin uptake sites: A quantitative autoradiographic study in the rat brain (1993) (19)
Design, synthesis and structure-activity relationship of rhenium 2-arylbenzothiazoles as β-amyloid plaque binding agents. (2013) (19)
Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. (2021) (18)
No effect of dopamine depletion on the binding of the high‐affinity D2/3 radiotracer [11C]FLB 457 in the human cortex (2010) (17)
Why we need two cutoffs for amyloid imaging: Early versus Alzheimer's-like amyloid-positivity (2012) (17)
Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography. (1984) (17)
Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson’s Disease (2013) (17)
Positron emission tomography of the heart. (1983) (16)
Synthesis of high specific activity 125I‐ and 123I‐labelled enantiomers of 2,5‐dimethoxy‐4‐iodophenylisopropylamine (DOI) (1988) (16)
Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. (2016) (16)
Synthesis of 123I‐and labelled 5‐iodo‐6‐nitroquipazine (1994) (15)
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase. (2004) (15)
Synthesis of 2,3-dimethoxy-5-iodobenzoic acid (1991) (15)
Lipophilic 11C‐labelled thioflavin‐T analogues for imaging amyloid plaques in alzheimer's disease (2001) (15)
Binding Potency of 6‐Nitroquipazine Analogues for the 5‐Hydroxytryptamine Reuptake Complex (1994) (14)
Synthesis and evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. (2002) (14)
P2-031 Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid pet tracer, PIB, in the same manner as human brain amyloid (2004) (14)
Human Biodistribution and Dosimetry of the D2/3 Agonist 11C-N-Propylnorapomorphine (11C-NPA) Determined from PET (2009) (14)
Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults (2016) (14)
Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories (2020) (14)
Amyloid-Beta Deposition is Associated with Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively Normal Elderly. (2017) (14)
CHAPTER 44 – Characterization of the Radiolabeled Metabolites of [18F]Altanserin: Implications for Kinetic Modeling (1998) (14)
What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies (2020) (14)
Positron emission tomography radiochemistry. (2003) (13)
Amyloid imaging with Pittsburgh Compound B (2005) (12)
A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of Aβ load (2018) (11)
Quantification of 5-HT1A and 5-HT2A receptor Binding in Depressed Suicide Attempters and Non-Attempters (2019) (11)
An efficient synthesis of the precursors of [11C]MDL 100907 labeled in two specific positions (1999) (11)
Comparison of longitudinal Aβ in nondemented elderly and Down syndrome (2019) (11)
Amyloid Imaging with PET in Alzheimer’s Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects (2009) (11)
[125I]5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytrrptamine uptake complex. II. In vivo studies in rats (1993) (11)
Radiohalogens for PET Imaging (2005) (10)
Whatever happened to Pittsburgh Compound-A? (2008) (10)
The Use of Isotopic Nitrogen as a Biochemical Tracer (1982) (10)
Quantitative and statistical analyses of PET imaging studies of amyloid deposition in humans (2004) (9)
The Centiloid Scale: Standardization of amyloid imaging measures (2013) (9)
Relationship of amyloid-β1–42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study (2019) (9)
Relationships Between Executive Control Circuit Activity, Amyloid Burden, and Education in Cognitively Healthy Older Adults. (2019) (9)
PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer’s disease progression in Down syndrome (2021) (9)
FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment (2008) (9)
An Aβ Sequestration Approach Using Non-Antibody Aβ Binding Agents (2005) (9)
Synthesis and evaluation of high affinity, aryl-substituted [18F]fluoropropylbenzamides for dopamine D-2 receptor studies. (1992) (8)
Synthesis of 1-[2',5'-dimethoxy-4'-(β-fluoroethyl)phenyl]-2-aminopropane: studies related to 18F-labeled serotonin receptor ligands (1988) (8)
Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. (2013) (8)
Fluoroalkylbenzenes: Synthesis of (S)-2.3-Dimethoxy-5-[(3-fluoro)propyll-6-hydroxy-N-](1-ethyl-2-pyr-rrolidinyl)methyllbenzamide (1991) (8)
Synthesis of 122I- and 125I-labelled meta-dimethoxy-N,N-dimethyliodophenylisopropylamines (1986) (8)
Comparison of the binding of 3′-F-PiB and PiB in human brain homogenates (2008) (8)
Development of a PET radioligand selective for cerebral amyloid angiopathy. (2020) (7)
Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization (2021) (7)
O3-03-05 Human amyloid-imaging studies in controls, mild cognitive impairment and Alzheimer's disease using Pittsburg compound-B (2004) (7)
Amyloid Imaging and (What is “Normal”?) Aging (2009) (7)
R(−)-2,5-Dimethoxy-4-77bromoamphetamine [77Br-R(−)DOB]: a novel radioligand which labels a 5-HT binding site subtype (1988) (7)
A radiosynthesis of [F‐18]fluoromisonidazole (1989) (7)
Stereoconservative synthesis of the enantiomerically pure precursors of [11C](+)-McN 5652 and [11C](-)-McN 5652 (1998) (7)
High pressure nucleophilic fluoride-ion substitution reactions: formation of fluoroalkylbenzenes (1996) (7)
Associations of equol‐producing status with white matter lesion and amyloid‐β deposition in cognitively normal elderly Japanese (2020) (7)
[18F]FDG, [11C]PiB, and [18F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline (2019) (7)
P2-178 Species-dependent formation and identification of the brain metabolites of the amyloid imaging agent [11C]PIB (2004) (7)
Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen (2020) (7)
Human Biodistribution and Dosimetry of the PET Radioligand [11C]Flumazenil (FMZ) (2012) (6)
JNM Supplement on Molecular Radiotherapy (2005) (6)
Association between Brain Amyloid, White Matter Hyperintensities and Hypometabolism, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. (2019) (6)
Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia (2022) (6)
Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals (2019) (6)
[18F]Altanserin PET Studies of Serotonin-2A Binding: Examination of Nonspecific Component (1998) (6)
An open‐label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)‐(–)‐O‐desmethylvenlafaxine and racemic O‐desmethylvenlafaxine (2018) (5)
An Abeta sequestration approach using non-antibody Abeta binding agents. (2005) (5)
Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome (2021) (5)
Human amyloid-imaging studies with Pittsburgh Compound-B in mild cognitive impairment (MCI): Is MCI the critical period of amyloid plaque deposition? (2005) (5)
11C-PIB PET imaging in the differential diagnosis of dementia (2006) (5)
Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women (2019) (4)
No interruption of lactation is needed after (11)C-WAY 100635 or (11)C-raclopride PET. (2005) (4)
Optimal time window for standardized uptake ratio as a simplified measure of PIB retension (2007) (4)
Association of plasma and cortical beta-amyloid is modulated by APOE ε4 status. (2014) (4)
Synthesis and evaluation of a radioiodinated benzothiazole derivative as a radioligand for in vivo quantitation of β‐amyloid deposits in aging and alzheimer's disease (2001) (4)
Positron Emission Tomography Agents for Central Nervous System Drug Development Applications (2005) (4)
In vivo amyloid deposition and neuropathological findings after humanized amyloid β-specific monoclonal antibodies therapy in a patient with Alzheimer's disease (2009) (4)
Radiotracer Studies of Thermal Hydrogen Abstraction Reactions by Atomic Fluorine (1978) (4)
PiB PET/CT identification of meningiomas is not due to presence of amyloid-beta within tumors (2012) (4)
Kinetic Modeling of Serotonin-1A Binding in Monkeys Using [11C]WAY 100635 and PET (1996) (4)
Quantitative in vitro and ex vivo autoradiography of the alpha 2-adrenoceptor antagonist [3H]atipamezole. (1992) (4)
Amphetamine-Induced Dopamine Release Greater in Ventral Than in Dorsal Striatum (2001) (4)
In vivo evaluation and imaging of a lipophilic derivative of Congo red for amyloid assessments (2001) (4)
Synthesis and β-amyloid binding properties of rhenium 2-phenylbenzothiazoles (2009) (4)
Simplified quantification of PIB amyloid imaging PET studies (2005) (4)
F-TO-HF Reactions. The importance of non-equilibrium effects in moderated nuclear recoil experiments (1980) (4)
P-029 Correlation of regional in VIVO pittsburgh compound-B (PIB) retention with in vitro PIB, Aβ levels, and amyloid plaque density: Validation of PIB-PET in postmortem human brain (2007) (3)
Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders (2022) (3)
Direct Correlations of [H-3]Flutemetamol Binding with [H-3]PiB Binding and Amyloid-beta Concentration and Plaque Load in [C-11]PiB Imaged Brains (S34.002) (2012) (3)
The Relationship of Current Cognitive Activity to Brain Amyloid Burden and Glucose Metabolism. (2018) (3)
Impact of exercise on caudate and putamen in a non-human primate model of Parkinson's disease (2008) (3)
Progression of Regional Cerebral Glucose Metabolic Abnormalities in Alzheimer's Disease (1987) (3)
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous. (2021) (3)
Arterial stiffness is associated with amyloid deposition in the brain independent of blood pressure (2013) (3)
Recoil 18F chemistry. Superexcited molecules from non-thermal F-for-F substitution in CF4 (1982) (3)
In vivo evidence for reduced striatal vesicular monoamine transporter (VMAT2) availability in cocaine abusers (2012) (3)
Rapid labeling of radiopharmaceuticals with iodine-122 (1986) (2)
Longitudinal PIB measures in control, MCI, and AD subjects (2008) (2)
IC-103-05 Pittsburgh compound-B four years later: What have we learned, what lies ahead? (2006) (2)
In Vivo Fibrillar (cid:2) -Amyloid Detected Using [ 11 C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults (2011) (2)
LONGITUDINAL CHANGE OF NEUROIMAGING AND CLINICAL MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE (2014) (2)
[O-15] Water and PIB PET imaging in Alzheimer's disease and mild cognitive impairment (2006) (2)
Imaging the pathology of Alzheimer’s disease: Building on a century-Old blueprint (2006) (2)
Serotonin Transporter Binding In Vivo (2001) (2)
Development of Benzothiazole Amyloid-Imaging Agents (2004) (2)
Comparative evaluation of template-based region sampling for PiB PET data analysis (2010) (2)
X-34 and other congo red-type amyloid binding agents as in vivo amyloid probes (2000) (2)
Radiopharmaceutical space. (2006) (2)
Elevated PiB precedes dementia in autosomal dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (2)
Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders (2022) (2)
Evaluation of a commercial radiochromatography module as an arterial blood activity monitor (2008) (2)
P1-231: Correlation of amyloid deposition with local and distal glucose metabolism in cognitively normal elderly, MCI and Alzheimer's disease (2008) (2)
OPL204 Amyloid imaging in Lewy Body Dementia with 11C-PIB-PET (2005) (2)
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study (2023) (2)
IC-103-04 Amyloid burden correlates with cognitive function in normal aging, MCI and AD (2006) (2)
Overall Radio-HPLC Design (1986) (2)
Nucleophilic aromatic substitution reactions with the fluoride ion : formation of 5-fluoro-indanones and indandiones related to atipamezole (1993) (2)
F-to-HF reactions. VIII. Nonthermal complications for the CHF/sub 3//C/sub 3/F/sub 6//C/sub 2/F/sub 6/ moderated nuclear recoil system (1982) (2)
Evaluation of reference tissue models for quantification of [11C] Pittsburgh compound B dynamic PET studies (2006) (2)
Use of PONS as a normalizing region for [c-11]pib-pet scans: Effect on subject classification (2011) (2)
Synthesis of 2,3-Dimethoxy-5-iodobenzoic Acid. (1992) (2)
R(-)-2,5-Dimethoxy-4-77Bromoamphetamine(77Br-R(-)DOB): A novel radioligand which labels a 5-HT binding site subtype (2004) (2)
Statistical Methods for Processing Neuroimaging Data from Two Different Sites with a Down Syndrome Population Application (2020) (2)
First PET Study with a Benzothiazol Amyloidimaging Agent (PIB) in Alzheimer’s Disease Patients and Healthy Volunteers (2004) (2)
RADIOHALOGEN-LABELED IMAGING AGENTS. 3. COMPOUNDS FOR MEASUREMENT OF BRAIN BLOOD FLOW BY EMISSION TOMOGRAPHY (1985) (1)
ACRIN-PA 4004 study: Comparison of [F-18] flutemetamol and [C-11] PiB in normal control and Alzheimer's subjects (2011) (1)
Low binding of the amyloid PET tracer, PIB, to transgenic PS1/APP mouse brain compared to human AD brain explained by Bmax (2005) (1)
Platelet labeling and positron emission tomography in the detection of sites of vascular injury (1985) (1)
O3-03-04 Novel approaches for non-invasive optical detection of amyloid-β plaques in vivo (2004) (1)
INCREASES IN PIB RETENTION ARE ASSOCIATED WITH INCREASED CEREBRAL GLUCOSE METABOLISM IN COGNITIVELY NORMAL ELDERLY: ROLE FOR COMPENSATORY HYPERMETABOLISM? (2016) (1)
Histological characterization of PIB binding to amyloid plaques in Alzheimer’s disease (2005) (1)
P1-379: In vivo detection of Alzheimer's disease–linked Aβ peptide accumulation in the lens (2008) (1)
Dose Dependency of Amphetamine-Induced [11C]Raclopride Binding Parameter Changes (1998) (1)
ASSOCIATIONS BETWEEN Aβ AND TAU IN ADULTS WITH DOWN SYNDROME (2019) (1)
Subjective cognition and ‘neuroticism,' but not depressive symptoms, are associated with beta-amyloid deposition in cognitively normal elderly (2013) (1)
ADNI PiB Studies (2009) (1)
for Labeling Platelets (1985) (1)
The high-affinity peripheral benzodiazepine receptor ligand [C-11]DAA1106 results in improved delineation of neuroinflammatory lesions in a rodent model of disease compared to [C-11]PK11195 (2006) (1)
Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study (2012) (1)
Progressive white matter abnormalities in autosomal dominant Alzheimer's disease: Results of the DIAN study (2012) (1)
Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation (2012) (1)
Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation (2012) (1)
Before and After Amphetamine (2002) (1)
IC-P-127 Non-invasive early detection of beta-amyloid molecular pathology by quasi-elastic light scattering in vivo (2006) (1)
On the mechanism of the thermal F + C2H4 reaction. the molecular elimination of HF from chemically activated C2 H4F radicals (1983) (1)
Human dosimetry of the PET radioligand [C-11]flumazenil (FMZ) (2009) (1)
IC-P-016 Imaging of cerebral amyloid angiopathy with Pittsburgh compound B (2006) (1)
In Pre-Clinical AD Small Vessel Disease is Associated With Altered Hippocampal Connectivity and Atrophy. (2022) (1)
Low untreated systolic blood pressure over 18 years is associated with survival free of dementia age 90+ (2022) (1)
Amyloid imaging of cerebral amyloid angiopathy (2007) (1)
[F-18]AV-1451 PET IN NON-DEMENTED ADULTS WITH DOWN SYNDROME IS RELATED TO BOTH AMYLOID AND COGNITION (2017) (1)
Evaluation of amyloid and tau PET quantitation methods using a 3D‐printed anatomically accurate brain phantom (2020) (1)
Amyloid imaging with Pittsburgh Compound-B in late-life depression (2005) (1)
Comparison of MR-based with 511-keV transmission-based attenuation correction in neuro FDG PET/MR (2014) (1)
Preventive immunization of aged and juvenile non-human primates to beta-amyloid (2012) (1)
An accurate and computationally efficient method for voxel-by-voxel estimation of the Pittsburgh compound B distribution volume ratio (2008) (1)
BINDING OF PITTSBURGH COMPOUND B TO BOTH NORMAL AND ABNORMAL WHITE MATTER IN ELDERLY COGNITIVELY NORMAL CONTROL (2014) (1)
O3-01-02 Early, premorbid detection of beta-amyloid pathology by non-invasive in vivo quasi-elastic light scattering in the lens (2006) (1)
Predicting the time to tau onset in Down syndrome using amyloid chronicity (2020) (1)
Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson disease: Most versus less affected side (2007) (1)
An Effect of Education on Memory-Encoding Activation in Subjective Cognitive Decline. (2021) (1)
BETA-AMYLOID DEPOSITION AND SUSPECTED NON-ALZHEIMER'S PATHOPHYSIOLOGY (SNAP) EXHIBIT DIFFERENT DECLINE PATTERNS AMONG COGNITIVE DOMAINS (2016) (1)
PIB PET 3-site stability study (2007) (1)
Cerebral Amyloid Related Alterations in Neuronal Metabolism and the Contribution of Multimodal Measures of Vascular Function. (S8.003) (2014) (1)
Gender-specific aging reductions in [11C-carbonyl] WAY100635 binding: Not an effect of atrophy (2000) (1)
Conversion to MCI and amyloid-positivity in normal controls (2013) (1)
Heritability of regional brain volumes in large-scale neuroimaging and genetic studies (2017) (1)
F‐to‐HF reactions. IX. Nonthermal complications for the CH4/C3F6/C2F6 moderated nuclear recoil system (1982) (1)
P2-285 Voxel-based analyses of pittsburgh Compound-B and FDG in AD (2006) (1)
Pharmacologic and pharmacokinetic equivalence studies of GE-067 to PiB (2009) (1)
IC-PL2: Amyloid imaging: Developments, challenges, future direction (2008) (0)
Effect of cognitively and physically stimulating activities on PiB-PET (2013) (0)
O1-05-01 Cortical amyloid deposition related to failure of hippocampal activation (2007) (0)
The ability to increase extracellular GABA predicts frontal cortical gamma synchrony (2008) (0)
PREDICTING RESILIENCY AGAINST AMYLOID-BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDEST-OLD (2018) (0)
IC-P-019 LONGITUDINAL ACCUMULATION OF b AMYLOID ON PET IN DEMENTIAWITH LEWY BODIES AND RELATIONSHIP TO CLINICAL DISEASE PROGRESSION PREDICTING RESILIENCYAGAINST AMYLOID-BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDEST-OLD (2018) (0)
O3-06-08 Pattern of amyloid plaque deposition with Pittsburgh compound-B (PIB) in mild cognitive impairment (2006) (0)
The application of amyloid-imaging to the diagnosis and treatment of Alzheimer’s disease (2005) (0)
Synthesis and structure-activity relationship of Tc/Re 2-arylbenzothiazoles as {beta}-amyloid imaging agents (2012) (0)
Trans-cortical correlations of Pittsburgh Compound-B in cognitively normal elderly, MCI and AD: Implications for the natural history of amyloid deposition (2010) (0)
In Vivo Imaging of Alzheimer Pathology in Transgenic Mice using Multiphoton Microscopy (2004) (0)
S2-04-04 Imaging and therapeutic approaches for β-sheet structures in prion and Alzheimer's diseases (2004) (0)
Further validation of [11C]FLB 457 as a tool to measure prefrontal cortical DA release (2010) (0)
Imaging the Pathology of Alzheimer's Disease: Amyloid-Imaging with PET (2003) (0)
Multivariate analysis of PIB PET imaging studies (2006) (0)
Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans (2021) (0)
P2-019: Differential labeling of amyloid plaques and tangles with 6-CN-PiB: Implications for in vivo PiB PET imaging (2008) (0)
Pittsburgh compound-B does not detect cotton wool plaques in PS-1 mutation carriers (2013) (0)
FDG metabolism in the DIAN study of autosomal dominant Alzheimer's disease (2012) (0)
COGNITIVE IMPAIRMENTAND INCREASED ALZHEIMER’S-LIKE PATHOLOGY IN CRND8 APP TRANSGENIC MICE (2013) (0)
Chapter 39 – Imaging Inflammation (2005) (0)
Use of partial least squares to relate yearly PiB DVR to clinical covariates in non-demented subjects (2009) (0)
Effect of cognitively and physically stimulating activities on PiB-PET (2013) (0)
Brain PET Oral 6: Neurodegenerative Disorders (2009) (0)
IC-P-210 COMPARISON OF IN VIVO [F-18]AV-1451 OFF-TARGET RETENTION IN AFRICAN- AMERICANS AND CAUCASIANS (2018) (0)
LOWER REGIONAL β-AMYLOID BURDEN IN JAPANESE THAN AMERICAN APOE ε4-NEGATIVE ELDERLY (2019) (0)
P2-328 Imaging of cerebral amyloid angiopathy with Pittsburgh Compound B (2006) (0)
Cognitive trajectories associated with beta-amyloid deposition in the nondemented oldest-old (2012) (0)
DETERMINATION OF NEURITIC VERSUS DIFFUSE PLAQUE CONTRIBUTION TO SIGNAL DERIVED FROM CN-FLUTEMETAMOL (2017) (0)
Human dosimetry of the novel D2/3 agonist [11C]N-propylnorapomorphine (NPA) (2008) (0)
1008 Sleep Efficiency Moderates The Relationship Between Beta-Amyloid And Memory Retention (2018) (0)
Assessing brain amyloid in nondemented adults with Down syndrome (2012) (0)
P2-097: Amyloid-imaging in dementias of uncertain etiology with Pittsburgh compound B (2008) (0)
SELECTIVITY OF PET AMYLOID IMAGING LIGANDS IN THE ALZHEIMER’S DISEASE NEUROPATHOLOGY SPECTRUM (2019) (0)
CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH CEREBRAL BLOOD FLOW AND METABOLISM BUT NOT AMYLOID BURDEN OR BRAIN ATROPHY IN COGNITIVELY NORMAL ELDERLY (2014) (0)
CORRESPONDENCE BETWEEN [C-11]PIB PET AND POST-MORTEM MEASURES OF AMYLOID LOAD IN THE PRECUNEUS: THE ROLE OF DIFFUSE AB PLAQUES (2014) (0)
BINDING OF PITTSBURGH COMPOUND B TO BOTH NORMAL AND ABNORMAL WHITE MATTER IN ELDERLY COGNITIVELY NORMAL CONTROLS (2014) (0)
Cognitive trajectories associated with beta-amyloid deposition in the nondemented oldest-old (2012) (0)
Amyloid imaging with PIB associated with impaired memory function on fMRI (2007) (0)
Longitudinal study of amyloid deposition in carriers of presenilin-1, presenilin-2 and APP mutations (2009) (0)
Development and Application of b-Amyloid Imaging Agents in Alzheimer’s Disease (2016) (0)
Comparison of longitudinal [11C]PiB change measures and impact of CSF dilution correction (2011) (0)
The high‐affinity peripheral benzodiazepine receptor ligand [11C]DAA1106 can be used to image microglia in animal models of Parkinson's disease and neuroinflammation in vivo using PET. (2007) (0)
Amyloid Deposition and Hippocampal Volume as Predictors of Incident Dementia in Non-Demented Very Elderly Subjects (IN3-2.004) (2013) (0)
Regional correspondence of ante-mortem and post-mortem amyloid load (2011) (0)
dominant Alzheimer disease Cerebral perfusion alterations and cerebral amyloid in autosomal (0)
Amyloid imaging in nondemented oldest-old (2011) (0)
O1-04-01 Quantitative evaluation of PIB PET and FDG PET in early cognitive impairment (2007) (0)
β-amyloid plaques in a PiB-PET negative subject: Implications for sensitivity of amyloid imaging in vivo (2009) (0)
Hippocampal volume loss is associated with increased A-beta levels in the precuneus in mild cognitive impairment (2009) (0)
Regular exercise training protects against MPTP-damage to nigrostriatal dopamine neurons in nonhuman primates (2010) (0)
P2-186 In vivo imaging of prion amyloid deposits (2004) (0)
Radioligands for PET Studies of Serotonin 5-HT2A Receptors (1998) (0)
Early Striatal Perfusion Deficits in Autosomal Dominant Alzheimer Disease Detected with Arterial Spin Labeled MRI. (P6.311) (2014) (0)
P1-128 Non-invasive early detection of beta-amyloid molecular pathology by quasi-elastic light scattering in vivo (2006) (0)
Sources of variability in the PIB PET tissue time–activity data (2008) (0)
COMPARISON OF IN VIVO [F-18]AV-1451 OFF-TARGET RETENTION IN AFRICAN AMERICANS AND CAUCASIANS (2018) (0)
HEMODYNAMIC CONNECTIVITY MEASUREMENTS FOLLOW NEURONAL CONNECTIVITY CHANGES IN A MOUSE MODEL OF AMYLOIDOSIS: CONSIDERATIONS FOR FUNCTIONAL CONNECTIVITY MRI (2017) (0)
Imaging of D2 agonist binding sites in healthy human subjects with [11C]NPA: Preliminary validation and reproducibility studies (2008) (0)
Hippocampal volume loss is associated with increased A-beta levels in the precuneus in mild cognitive impairment (2009) (0)
PREDICTING RESILIENCY AGAINST AMYLOID-BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDEST-OLD (2018) (0)
Neuropsychological profiles of asymptomatic adults with Down syndrome and evidence of amyloid deposition (2013) (0)
High Pressure Nucleophilic Fluoride-Ion Substitution Reactions: Formation of Fluoroalkylbenzenes. (1996) (0)
Amyloid imaging in the 80+ population and cognitive trajectories (GEMS) (2015) (0)
AMYLOID DEPOSITION AND BRAIN STRUCTURE AS LONG-TERM PREDICTORS OF DEMENTIA IN COGNITIVELY NORMAL AND MCI INDIVIDUALS (2017) (0)
Longitudinal changes in fibrillar amyloid-beta deposition across the cognitive spectrum: Effect of the APOE4 allele (2011) (0)
Increases in Pittsburgh compound B retention are associated with increased cerebral glucose metabolism in cognitively normal elderly: Role for compensatory hypermetabolism? (2012) (0)
Use of thioflavin derivatives of the selected radio amyloid imaging to assess anti-amyloid therapies (2005) (0)
Increased survival of nigrostriatal dopaminergic neurons following a toxic MPTP insult in the exercising primate: A [11C]DTBZ PET study (2008) (0)
HUMAN AMYLOID IMAGING IN CONTROLS, MCI AND AD WITH THE THIOFLAVIN-T DERIVATIVE, PIB (2003) (0)
Longitudinal study of amyloid deposition in carriers of presenilin-1, presenilin-2 and APP mutations (2009) (0)
45. Gender differences in aging effect on the 5-HTlA receptor with [11C-carbonyl]way100635 PET (2000) (0)
Characterization of flutemetamol binding in autopsy brains from [C-11]PiB imaged subjects (2011) (0)
CORRESPONDENCE BETWEEN [C-11]PIB PET AND POST-MORTEM MEASURES OF AMYLOID LOAD IN THE PRECUNEUS: THE ROLE OF DIFFUSE Aβ PLAQUES (2014) (0)
IC-P2-110: Classification of amyloid-positivity in cognitively normal elderly controls: Comparison of objective approaches with visual reads (2008) (0)
Assessing the threshold for in vivo detection of amyloid-beta plaques (2010) (0)
Evaluation of serotonin 1A receptor binding in diabetes and depression (2005) (0)
CEREBRAL AMYLOID-β AND GAIT SPEED IN OLDER ADULTS WITHOUT DEMENTIA: INFLUENCE OF COGNITION AND APOE-E4 GENOTYPE (2016) (0)
Effect of cognitively stimulating activities on PiB-PET in cognitively normal elderly (2015) (0)
Possible relationship of serotonin transporter to dopamine D2/D3 receptor binding after recovery from eating disorders (2008) (0)
O2-03-05 (2006) (0)
Added Value of PET ligands (2009) (0)
A multivariate approach for mapping longitudinal changes in amyloid deposition (2010) (0)
Functional connectivity alterations of dorsal premotor cortex subregions in Parkinson's disease (2018) (0)
Regional differences in amyloid load and cortical cholinergic plasticity during the progression of Alzheimer's disease (2010) (0)
CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH CEREBRAL BLOOD FLOW AND METABOLISM BUT NOT AMYLOID BURDEN OR BRAIN ATROPHY IN COGNITIVELY NORMAL ELDERLY (2014) (0)
Associations between cognition, Aβ, and tau in adults with Down syndrome (2021) (0)
Benzothiazolderivatforbindelser, compositions and uses thereof (2004) (0)
DETERMINATION OF NEURITIC VERSUS DIFFUSE PLAQUE CONTRIBUTION TO SIGNAL DERIVED FROM CN-FLUTEMETAMOL (2017) (0)
IC-P2-124: Gray matter changes in cognitively normal control subjects with PiB retention (2008) (0)
Longitudinal PET imaging identifies earliest stages of Aβ accumulation in Down syndrome (2021) (0)
VERBAL ASSOCIATIVE BINDING IS ASSOCIATED WITH AMYLOID-BETA DEPOSITION IN SELF-REFERRED SUBJECTIVE MEMORY COMPLAINERS BUT NOT IN COGNITIVELY NORMAL VOLUNTEERS (2016) (0)
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection (2016) (0)
Amyloid imaging in nondemented oldest old (2011) (0)
Altered 5-HT1A and 5-HT2A receptor interactions in anorexia and bulimia nervosa (2008) (0)
Early striatal amyloid deposition distinguishes down syndrome and autosomal dominant Alzheimer’s disease from late-onset amyloid deposition (2015) (0)
WHY FEW SURVIVE COGNITIVELY NORMAL TO VERY OLD AGE MAY BE KEY TO PREVENTING DEMENTIA, ALZHEIMER’S DISEASE (2019) (0)
APOE e4 status modulates the association of plasma and cortical Aβ: Relation of plasma Aβ and [11C]PiB PET in the ADNI cohort (2011) (0)
Title Large-scale genomics unveil polygenic architecture of human cortical surface area Permalink (2015) (0)
Alzheimer research forum live discussion: Imaging in Alzheimer's disease: the current state of affairs. (2005) (0)
P2-063 In vivo dynamics of amyloid associated neuritic dystrophy before and after anti-Aβ immunotherapy (2004) (0)
Human biodistribution and dosimetry of the D2/3 agonist [11C]N-propylnorapomorphine (NPA) from Positron Emission Tomography (2008) (0)
IC-P-012 CONFOCAL ANALYSIS OF FLUORESCENT SIGNAL DERIVED FROM CN-FLUTEMETAMOL LABELED DIFFUSE AND NEURITIC PLAQUES IN ALZHEIMER’S DISEASE (2018) (0)
Amyloid imaging in Alzheimer’s disease and dementia with lewy bodies with 11C-PIB-PET (2005) (0)
Using radiolabeled thioflavin derivatives in amyloid imaging for evaluation of anti-amyloid therapies (2005) (0)
COMPARISON OF STRIATAL LONGITUDINAL CHANGES IN AMYLOID DEPOSITION IN NON-DEMENTED ELDERLY AND DOWN SYNDROME (2018) (0)
Cognitive correlates of striatal amyloid deposition in preclinical and early autosomal dominant Alzheimer's disease (2013) (0)
PET imaging of 5-HT1A receptors in late-life depression: Relationship to treatment response (2005) (0)
Tau imaging : pathologic correlations 3 Number of words in the body of the manuscript : 3535 Number of figures : 5 Number of color figures : 4 Number of tables : 0 (2016) (0)
Regional correspondence of antemortem and postmortem amyloid load (2011) (0)
BOTH FULL-LENGTH AND PYROGLUTAMATE AMYLOID-BETA ARE ASSOCIATED WITH PITTSBURGH COMPOUND-B BINDING IN THE PRECUNEUS ACROSS CLINICAL STAGES OF ALZHEIMER’S DISEASE (2019) (0)
Characterization of flutemetamol binding in autopsy brains from [C-11]PiB-imaged subjects (2011) (0)
Cluster analysis of PIB and FDG PET measures in control, MCI, and Alzheimer's disease subjects (2008) (0)
β-amyloid plaques in a PiB-PET negative subject: Implications for sensitivity of amyloid imaging in vivo (2009) (0)
P2-312 PET imaging of microglia in a mouse model of Alzheimer’s disease (2006) (0)
ALZHEIMER-LIKE PATHOPHYSIOLOGICAL CHANGES IN THE NON-DEMENTED DOWN SYNDROME POPULATION (2017) (0)
O2-03-05 Early detection of Alzheimer’s disease-linked aβ peptide accumulation in the lens by non-invasive quasi-elastic light scattering (2007) (0)
Elevated PiB precedes dementia in autosomal-dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (0)
PET Imaging of Neurodegeneration With [18F]AV-1451 PET After Repetitive Traumatic Brain Injury (2019) (0)
Patterns of correlation between Aβ deposition and glucose metabolism across the spectrum of mild cognitive impairment to Alzheimer's disease (2009) (0)
P2-156 Development of amyloid-imaging agents for both pet and spect (2004) (0)
Arterial stiffness is associated with amyloid deposition in the brain independent of blood pressure (2013) (0)
CONFOCAL ANALYSIS OF FLUORESCENT SIGNAL DERIVED FROM CN-FLUTEMETAMOL LABELED DIFFUSE AND NEURITIC PLAQUES IN ALZHEIMER’S DISEASE (2018) (0)
Statistical modeling of longitudinal PiB retention (2010) (0)
Regional FDG hypometabolism associated with amyloid deposition in normal aging (2007) (0)
In vivo Detection of Early Alzheimer's Disease-Linked Aβ Peptide Accumulation in the Lens by Non-Invasive Quasi-Elastic Light Scattering (2010) (0)
Subjective cognition and neuroticism, but not depressive symptoms, are associated with beta-amyloid deposition in the cognitively normal elderly (2013) (0)
CHAPTER 6 – Autoradiography as a Tool for PET/SPECT Tracer Selection and Assessment (1996) (0)
Semi‐quantitative [11C]PiB and [15O]H2O PET measures of cerebrospinal fluid dynamics discriminate amyloid load but not cognitive status (2021) (0)
Binding of the amyloid-imaging PET tracer, Pittsburgh Compound-B, to post-mortem human brain tissue from the AN-1792 immunotherapy trial (2005) (0)
CHAPTER 6 Overall Radio-HPlC Design (0)
[FUNCTIONAL ANALYSIS BY THIN LAYER CHROMATOGRAPHY]. (1963) (0)
The high-affinity peripheral benzodiazepine receptor ligand [11C]DAA1106 can be used to image microglia in animal models of Parkinson's disease and neuroinflammation in vivo using PET: 48.4 (2007) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
IC-P-001 Imaging Alzheimer’s pathology in late-life depression with PIB-PET (2006) (0)
Cognitive follow-up in non-demented subjects with evidence of amyloid deposition using Pittsburgh Compound-B (PIB) (2007) (0)
IC-P2-102: Differential labeling of amyloid plaques and tangles with 6-CN-PiB: Implications for in vivo PiB PET imaging (2008) (0)
S14.02 - Imaging serotonergic and dopaminergic neurocircuits in eating disorders: New insight into behavior and treatment (2008) (0)
Radiotracer studies of unimolecular energy transfer (1981) (0)
POSITRON EMISSION TOMOGRAPHY AND PLATELET LABELLING IN THE STUDY OF ATHEROSCLEROSIS (1984) (0)
Progressive white matter abnormalities in autosomal-dominant Alzheimer's disease: Results of the DIAN study (2012) (0)
O1-05-01 (2006) (0)
Synthesis of 1-(2′,5′-Dimethoxy-4′-(β-fluoroethyl)phenyl)-2-aminopropane (III): Studies Related to 18F-Labeled Serotonin Receptor Ligands. (1989) (0)
FLUORINE-TO-HYDROGEN FLUORIDE REACTIONS. VIII. NONTHERMAL COMPLICATIONS FOR THE CHF3/C3F6/C2F6 MODERATED NUCLEAR RECOIL SYSTEM (1982) (0)
Identification of a Putative α-synuclein Radioligand Using an in silico Similarity Search. (2023) (0)
Nucleophilic Aromatic Substitution Reactions with the Fluoride Ion: Formation of 5-Fluoroindanones and Indandiones Related to Atipamezole. (2010) (0)
Template based PiB PET-image analysis: Template driven variability (2010) (0)
P2-369 Correlation analysis of the histofluorescence of an analogue of Pittsburgh Compound-B and Aβ peptide levels in Alzheimer’s disease (2006) (0)
Radiosynthesis, in vitro and in vivo evaluations of [3H]/[18F]CBD-2115 as first in class radiotracers for imaging 4R-tauopathies (2021) (0)
Use of pons as a normalizing region for [C-11]PIB PET scans: Effect on subject classification (2011) (0)
NMDA RECEPTOR LIGANDS AND MEMORY PROCESSING (1995) (0)
AMERICAN COLLEGE OF RADIOLOGY IMAGING NETWORK ACRIN PA 4004 EVALUATION OF THE ABILITY OF A NOVEL ( 18 F) AMYLOID LIGAND (( 18 F)3'-F-PIB) TO DISTINGUISH PATIENTS WITH A CLINICAL DIAGNOSIS OF ALZHEIMER'S DISEASE FROM COGNITIVELY NORMAL ELDERLY INDIVIDUALS (2009) (0)
Synthesis of high specific activity radiohalogenated amphetamine analogues for studies of the serotonin 5‐HT2 receptor (1989) (0)
0 IMETHY LIODOPHENY LI SOPROPY LAMINES (1986) (0)
P164. Investigation of noise-induced correlations in dual-biomarker parametric imaging from dynamic [C]PiB PET (2016) (0)
Longitudinal Changes in Amyloid Deposition in Normal Elderly, Mild Cognitive Impairment and Alzheimer's disease (2010) (0)
COMPARISON OF IN VIVO [F-18]AV-1451 OFF-TARGET RETENTION IN AFRICAN-AMERICANS AND CAUCASIANS (2018) (0)
Opening Mechanotransducer Channels (2005) (0)
P2-329 Amyloid burden correlates with cognitive function in normal aging, MCI and AD (2006) (0)
Elevated neurofibrillary tau levels emerge with subthreshold Aβ accumulation in Down syndrome (2021) (0)
Rapid brain scanning radiopharmaceutical (1987) (0)
Limitations of the moderated nuclear recoil technique for investigating thermal hydrogen abstraction reactions by atomic fluorine (1981) (0)
Distribution of 1-(2-Deoxy-2-fluoro-β-d-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts (2004) (0)
Generator produced I-122 labeled amines and diamines for brain blood flow measurements in neurologic disorders (1985) (0)
omarker for assessing signals of efficacy in early-stage AD clinical trials. P2-327 NEUROIMAGE STEREOLOGY: A MARKER FOR BRAIN AGING AND DEMENTIA (2006) (0)
Fluoroalkylbenzenes: Synthesis of (S)-2,3-Dimethoxy-5-((3-fluoro) propyl)-6-hydroxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide. (1992) (0)
Trans-cortical correlations of pittsburgh compound-B in cognitively normal elderly, MCI and Alzheimer's: Implications for the natural history of amyloid deposition (2010) (0)

This paper list is powered by the following services:

Other Resources About Chester Mathis

en.wikipedia.org

What Schools Are Affiliated With Chester Mathis?

Chester Mathis is affiliated with the following schools: